Home » Topics » New compound, BioWorld Science

New compound, BioWorld Science
RSS

New dopamine D4 receptor antagonists from Taisho and Nihon Nohyaku

Sep. 20, 1996

Mitochondrial benzodiazepine receptor (MBR) ligands as potential anxiolytics

Sep. 20, 1996

Glaxo Wellcome identifies potential anxiolytic agents

Sep. 20, 1996

AGN-193080, a peripherally acting alpha2-agonist from Allergan

Sep. 20, 1996

New topical triazole antifungal agent from Kaken

Sep. 20, 1996

Optically active triazole antifungal agent from Takeda

Sep. 20, 1996

Safe, broad-spectrum quinolones from Wakunaga

Sep. 20, 1996

New quinolone from Bayer undergoing extensive evaluation

Sep. 20, 1996

Potential new analgesic agent from SmithKline Beecham

Sep. 20, 1996

Orally active GH secretagogues with a short duration of action

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...